|
|
||||||||
![]() |
||||||||
|
| Table 1: | |||||
|
Clinical
Characteristics of the Hypertensive Emergency
|
|||||
|
Blood |
Funduscopic Findings |
Neurologic Status | Cardiac Findings | Renal Symptoms |
Gastrointestinal Symptoms |
| Usually
>220/140 mm Hg |
Hemorrhages, exudates, papilledema | Headache, confusion, somnolence, stupor, visual loss, seizures, focal neurologic deficits, coma | Prominent apical pulsation, cardiac enlargement, congestive heart failure | Azotemia, proteinuria, oliguria | Nausea, vomiting |
| Table 2: | |||
|
Triage
Evaluation: |
|||
|
|
Emergency | vs. | Uncontrolled Hypertension |
| Blood Pressure | |||
| Symptoms | SOB Chest Pain nocturia dysarthia weakness altered consciousness |
Headache |
|
| Examination | encephalopathy pulmonary edema renal insufficiency cerebrovascular accident acute coronary syndrome |
may have TOD clinical CVD present stable, often no TOD/CVD |
|
| Therapy | baseline
laboratory tests intravenous line monitor BP may initiate therapy in ED |
observe initiate/resume medication(s) increase dose of inadequate agent |
|
| Plan | Immediate
admission to monitored unit parenteral agents treat to initial goal BP additional diagnostic studies if needed |
arrange follow-up <24 hours to several days if no prior evaluation, schedule appointment | |
|
Copyright
2003 The Cleveland Clinic Foundation
|
| Table 3: | |||
|
Management
of Hypertensive Emergencies
|
|||
|
Agent
|
Dose
|
Onset/Duration
of Action (after discontinuation)
|
Precautions
|
| Parenteral Vasodilators | |||
| Sodium nitroprusside | 0.25-10 µg/kg/min as IV infusion | Immediate/2-3 min after infusion | Nausea, vomiting; with prolonged use may cause thiocyanate intoxication, methemoglobinemia, acidosis, cyanide poisoning; bags, bottles, and delivery sets must be light resistant |
| Nitroglycerin | 5-100 µg as IV infusion* | 2-5 min/5-10 min | Headache, tachycardia, vomiting, flushing, methemoglobinemia; requires special delivery system due to drug binding to PVC tubing |
| Nicardipine | 5-15 mg/hr IV infusion | 1-5 min/15-30 min, but may exceed 12 hr after prolonged infusion | Tachycardia, nausea, vomiting, headache, increased intracranial pressure; hypotension may be protracted after prolonged infusions |
| Diazoxide | 50-150 mg as IV bolus, repeated or 15-30 mg/min by IV infusion | 2-5 min/3-12 hr | Hypotension, tachycardia, aggravation of angina pectoris, nausea and vomiting, hyperglycemia with repeated injections |
| Fenoldapam mesylate | 0.1-0.3 µg/kg/min IV infusion | <5 min/30 min | Headache, tachycardia, flushing, local phlebitis, dizziness |
| Hydralazine | 5-20 mg as IV bolus or 10-40 mg IM; repeat every 4-6 hr | 10 min IV/>1hr (IV) 20-30 min IM/4-6 hr (IM) | Tachycardia, headache, vomiting, aggravation of angina pectoris, sodium & water retention and increased intracranial pressure |
| Enalaprilat | 0.625-1.25 mg every 6 hr IV | Within 30 min/12-24 hr | Renal failure in patients with bilateral renal artery stenosis, hypotension |
| Parenteral Adrenergic Inhibitors | |||
| Labetalol | 20-40 mg as IV bolus every 10 min; up to 2 mg/min as IV infusion | 5-10 min/2-6 hr | Bronchoconstriction, heart block, orthostatic hypotension, bradycardia |
| Esmolol | 500 µg/kg bolus injection IV or 50-100 µg/kg/min by infusion. May repeat bolus after 5 min or increase infusion rate to 300 µg/kg/min | 1-5 min/15-30 min | First-degree heart block, congestive heart failure, asthma |
| Phentolamine | 5-10 mg as IV bolus | 1-2 min/10-30 min | Tachycardia, orthostatic hypotension |
| *
Requires special delivery system hr=hour(s); min=minute; IV=intravenous; IM=intramuscular; PVC=polyvinyl chloride |
|||
|
This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this web site. |
|
Copyright
2003 The Cleveland Clinic Foundation
|